Eczema Awareness Month: Top Healio stories highlight treatments, causes, comorbidities

Key takeaways:

• This year’s top eczema-related Healio story focused on an atopic dermatitis treatment that is connected with cutaneous T-cell lymphoma.
• Many headlines surrounding comorbidities also dominated headlines.

The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2024 focused on reducing stigma using social media.

More than 31 million people live with eczema in the United States. Although common, the condition continues to be stigmatized and misunderstood, according to the National Eczema Association (NEA).

The disease, which is categorized into seven types with atopic dermatitis being the most common, can range from mild dryness of the skin to debilitating redness, itchiness and inflammation covering the body.

This month, the NEA is hosting a social media-driven awareness campaign called “The Ecz-hibition,” where close-up photos of skin affected by eczema are posted with an accompanying poem about the hardships of living with this condition.

In light of Eczema Awareness Month, Healio Dermatology has compiled the top 10 most-read articles this year about eczema in hopes of raising awareness.

Dupilumab treatment for AD linked to cutaneous T-cell lymphoma development

The most read story this year about eczema involved a recently published study on the association between dupilumab and an increased risk for cutaneous T-cell lymphoma in patients taking the drug for AD. Read more.

AD treatments with greatest efficacy may also cause most harm

A study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting show that the most effective treatments for AD may also be the most harmful. Read more.

Antihypertensive medications associated with eczematous dermatitis in older patients

Due to a small increase in eczematous dermatitis, older adults taking antihypertensive drugs should be monitored and this possibility considered when assessing for eczema, according to a study. Read more.

JAK inhibitors have ‘untapped potential’ in treatment of inflammatory skin diseases

At this year’s South Beach Symposium, a speaker promoted the potential of Janus kinase inhibitors to push the boundaries of efficacy in the treatment of inflammatory skin diseases. Read more.

FDA approves Zoryve for AD in adults, children

In July, the FDA approved Zoryve cream 0.15% for the treatment of mild to moderate AD in adult and pediatric patients aged 6 years and older. Read more.

AD may be linked to inflammatory bowel disease

An association between moderate to severe AD and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study. Read more.

Higher dietary sodium intake associated with increased risk for AD

Higher dietary sodium intake was associated with a higher risk for current AD, suggesting that a sodium-restricting diet may be a helpful intervention for disease management, according to a study. Katrina Abuabara, MD, MA, MSCE, associate professor of dermatology at University of California, San Francisco, and associate adjunct professor of epidemiology at UC Berkeley School of Public Health, weighed in. Read more.

Most patients with chronic hand eczema suffer from corticosteroid phobia

A new study found that the majority of patients with chronic hand eczema suffer from corticosteroid phobia, which negatively impacts treatment adherence. Read more.

Beneath the Surface: Exploring sodium’s effect on dermatologic disease

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts. In this edition, Gelfand spoke with Abuabara about the details and implications of her study on sodium’s effect on AD. Watch here.

Yeast and Zoryve: New findings provide better understanding of seborrheic dermatitis

In this final article, dermatologist Raj Chovatiya, MD, PhD, MSCI, spoke to Healio about his new findings in seborrheic dermatitis and how to best treat diverse patient groups with this condition. Read more.

Reference:

• Eczema Awareness Month. https://nationaleczema.org/eczema-awareness-month/. Accessed Oct. 11, 2024.